novo nordisk oral semaglutide fda approval has announced that the has approved the Wegovy® pill (once-daily 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults Novo Nordisk wins the oral

Other early side effects may include: Injection site reactions (redness, itching, bruising) usually mild and transient Headache Common Most gastrointestinal side effects are mild to moderate in severity and tend to diminish as the body adapts to the medication

Urinary tract infections (UTIs) are not listed as a common side effect of Ozempic in FDA labeling, yet patients and healthcare providers have reported this concern during GLP-1 therapy

GLP-1 (glucagon-like peptide-1) is a hormone produced in the intestines that is vital for regulating blood sugar levels and appetite

Therefore, it's recommended to consult with a healthcare professional before starting any new treatment regimen

it's the future